Addus HomeCare (ADUS) Q2 2026 earnings review
Steady Execution, Flawless Balance Sheet, Awaiting M&A
Addus delivered a fundamentally sound Q2 2026, combining stable 8.0% revenue growth with an 11.9% expansion in Adjusted EBITDA. The Personal Care and Hospice segments remain the primary growth engines, driven by favorable state rate increases (IL, TX) and solid operational execution. Most notably, the company's aggressive deleveraging over the past four quarters has pushed it into a net cash position. While the Home Health segment remains a drag and Personal Care same-store census experienced a slight dip, the overarching narrative is one of a highly disciplined operator with a fortress balance sheet, primed for significant capital deployment in the second half of the year.
🐂 Bull Case
Addus has successfully transitioned to a net cash position ($99.6M in cash vs $64.3M in bank debt), opening the door for massive capital deployment toward M&A without stressing leverage limits.
Despite a slight gross margin compression, Adjusted EBITDA grew nearly 12% YoY, indicating excellent operational cost management and G&A leverage.
🐻 Bear Case
The Home Health segment continues to experience revenue contraction (-2.8% organic YoY), burdened by declining visits per episode despite an increase in raw admissions.
While overall Personal Care hours grew, same-store average billable census actually declined YoY (49,955 vs 50,347), making the segment heavily reliant on state rate increases and higher hours-per-patient to drive revenue.
⚖️ Verdict: 🟢
Bullish. The business is generating substantial cash, successfully navigating the complex reimbursement landscape, and sits on a pristine balance sheet that virtually guarantees accretive M&A in the near future.
Key Themes
Aggressive Deleveraging Unlocks M&A Capacity
The most significant development over the past year is Addus's cash generation capability. The company brought its bank debt down from $173.0M in 25Q2 to just $64.3M this quarter, supported by $40.0M in operating cash flow. With $99.6M in cash on the books, Addus is officially net cash positive. Management has explicitly stated that scaling via acquisitions is the priority, and the current balance sheet provides roughly $577.8M in revolver availability to hunt 'Gentiva-sized' targets.
State Rate Increases Continue to Propel Personal Care
The Personal Care segment—78.4% of total revenue—benefited heavily from the compounding effects of rate increases in Texas (9.9% enacted late 2025) and Illinois (3.9% enacted Jan 2026). This regulatory tailwind allowed the segment to achieve 6.8% organic revenue growth despite underlying sluggishness in total patient counts.
Home Health Mismatch: More Admissions, Fewer Visits
A notable red flag exists within the Home Health unit metrics. While total volume (+5.4%) and new admissions (+9.8% to 5,016) showed robust growth, total visits plunged 6.5% YoY (88,516 vs 94,692). This severe drop in visits-per-admission drove a 2.8% organic revenue contraction. This implies either a severe shift toward less intensive (and lower reimbursed) patient profiles or operational struggles in staffing skilled nursing visits.
Hospice Accelerates Through Operational Synergies
Hospice was the standout organic performer, accelerating to 11.1% organic revenue growth (up from 7.7% in Q1). Average daily census (ADC) grew a healthy 6.5%, and revenue per patient day ticked up slightly. This validates management's 'bridge program' thesis—shifting eligible Home Health patients over to Hospice care where Addus has co-located operations.
Personal Care Census is Shrinking
A contradictory data point in the primary growth engine: Same-store average billable census actually declined to 49,955 from 50,347 a year ago. Revenue growth was entirely manufactured by a higher rate environment and an increase in average billable hours per census per month (up to 72.9 from 69.8). If state budgets tighten, the lack of raw volume growth will expose the top line.
Macro Tailwinds: Demand for Home-Based Settings
Management continues to cite strong, sustained demand for high-quality, cost-effective home care services. As national Medicaid MCOs face margin pressures, Addus’s ability to keep patients out of high-cost institutional settings (SNFs) aligns the company's financial interests directly with those of state and federal payers.
Technological Efficiency Driving Higher Fill Rates
While not explicitly detailed in the Q2 press release, the increase in average billable hours per month (72.9 vs 69.8) validates the ongoing success of the Caregiver App innovation discussed in prior quarters. By automating scheduling and matching caregivers to authorized hours more efficiently, Addus is effectively squeezing more revenue out of a flat patient base.
Other KPIs
Expanding. Up from 12.6% in 25Q2. The company effectively leveraged its G&A expenses, which grew only 1.8% YoY ($78.5M vs $77.1M) while revenues grew 8.0%. This discipline is what allows Adjusted EBITDA to outpace top-line growth.
Accelerating. Almost doubling the $22.5 million generated in the prior-year period. This massive jump underscores normalizing DSOs and effective working capital management across state payers.
Decelerating slightly. Compressed 40 basis points from 32.6% in 25Q2. This indicates that while rate increases are passing through, wage inflation and mandatory wage pass-throughs to caregivers are absorbing a large chunk of the top-line pricing benefit.
Guidance
Stable. The company did not provide specific quantitative financial guidance in the Q2 press release. Management noted they anticipate acting on 'meaningful synergies and uncovering further growth opportunities throughout the remainder of 2026', pointing clearly to an expectation of closing additional M&A deals.
Key Questions
The Home Health Disconnect
Home Health new admissions jumped almost 10% YoY, yet total visits declined 6.5%. Is this a deliberate shift away from therapy-heavy episodes, or are there localized clinical staffing shortages preventing you from fulfilling visits?
Personal Care Same-Store Census
Despite a favorable reimbursement backdrop and Caregiver App success driving up hours-per-patient, same-store billable census in Personal Care declined YoY. What are the specific bottlenecks to raw volume growth in your legacy markets?
M&A Thresholds and Capital Deployment
You are now in a net-cash position with over $570M in revolver availability. Given the stated desire for 'Gentiva-sized' targets, how has the valuation environment shifted, and are you willing to lever up past 2.0x for the right asset?